Blockchain Registration Transaction Record

SeaStar Medical Holds Interview with Benzinga to Discuss Breakthrough Therapies for Critically Ill Patients

SeaStar Medical Holding Corp. CEO, Eric Schlorff, discusses breakthrough therapies for critically ill patients with Benzinga. Learn about QUELIMMUNE, their FDA-approved treatment for pediatric patients with acute kidney injury, and their ongoing trials for a second therapeutic device with broad applications.

This news matters because SeaStar Medical's cutting-edge therapies have the potential to revolutionize treatment for critically ill patients, offering hope for those suffering from hyperinflammation and life-threatening conditions. The company's innovative approach could significantly impact the medical industry and improve outcomes for a wide range of serious conditions.